Literature DB >> 7595522

Chondroitin sulfate and chondroitin/keratan sulfate proteoglycans of nervous tissue: developmental changes of neurocan and phosphacan.

B Meyer-Puttlitz1, P Milev, E Junker, I Zimmer, R U Margolis, R K Margolis.   

Abstract

We have studied developmental changes in the structure and concentration of the hyaluronic acid-binding proteoglycan, neurocan, and of phosphacan, another major chondroitin sulfate proteoglycan of nervous tissue that represents the extracellular domain of a receptor-type protein tyrosine phosphatase. A new monoclonal antibody (designated 1F6), which recognizes an epitope in the N-terminal portion of neurocan, has been used for the isolation of proteolytic processing fragments that occur together with link protein in a complex with hyaluronic acid. Both link protein and two of the neurocan fragments were identified by amino acid sequencing. The N-terminal fragments of neurocan are also recognized by monoclonal antibodies (5C4, 8A4, and 3B1) to epitopes in the G1 and G2 domains of aggrecan and/or in the hyaluronic acid-binding domain of link protein. The presence in brain of these N-terminal fragments is consistent with the developmentally regulated appearance of the C-terminal half of neurocan, which we described previously. We have also used a slot-blot radioimmunoassay to determine the concentrations of neurocan and phosphacan in developing brain. The levels of both proteoglycans increased rapidly during early brain development, but whereas neurocan reached a peak at approximately postnatal day 4 and then declined to below embryonic levels in adult brain, the concentration of phosphacan remained essentially unchanged after postnatal day 12. Keratan sulfate on phosphacan-KS (a glycoform that contains both chondroitin sulfate and keratan sulfate chains) was not detectable until just before birth, and its peak concentration (at 3 weeks postnatal) was reached approximately 1 week later than that of the phosphacan core protein. Immunocytochemical studies using monoclonal antibodies to keratan sulfate (3H1 and 5D4) together with specific glycosidases (endo-beta-galactosidase, keratanase, and keratanase II) also showed that with the exception of some very localized areas, keratan sulfate is generally not present in the embryonic rat CNS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7595522     DOI: 10.1046/j.1471-4159.1995.65052327.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  23 in total

1.  The chondroitin sulfate proteoglycans neurocan and phosphacan are expressed by reactive astrocytes in the chronic CNS glial scar.

Authors:  R J McKeon; M J Jurynec; C R Buck
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

2.  Neurocan is upregulated in injured brain and in cytokine-treated astrocytes.

Authors:  R A Asher; D A Morgenstern; P S Fidler; K H Adcock; A Oohira; J E Braistead; J M Levine; R U Margolis; J H Rogers; J W Fawcett
Journal:  J Neurosci       Date:  2000-04-01       Impact factor: 6.167

3.  DSD-1-proteoglycan is the mouse homolog of phosphacan and displays opposing effects on neurite outgrowth dependent on neuronal lineage.

Authors:  J Garwood; O Schnädelbach; A Clement; K Schütte; A Bach; A Faissner
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

4.  Intact aggrecan and fragments generated by both aggrecanse and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury.

Authors:  M L Lemons; J D Sandy; D K Anderson; D R Howland
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

5.  Embryonic neurons adapt to the inhibitory proteoglycan aggrecan by increasing integrin expression.

Authors:  M L Condic; D M Snow; P C Letourneau
Journal:  J Neurosci       Date:  1999-11-15       Impact factor: 6.167

6.  Expression of hyaluronan and the hyaluronan-binding proteoglycans neurocan, aggrecan, and versican by neural stem cells and neural cells derived from embryonic stem cells.

Authors:  Mary Abaskharoun; Marie Bellemare; Elizabeth Lau; Richard U Margolis
Journal:  Brain Res       Date:  2010-02-20       Impact factor: 3.252

Review 7.  Extracellular matrix of the central nervous system: from neglect to challenge.

Authors:  Dieter R Zimmermann; María T Dours-Zimmermann
Journal:  Histochem Cell Biol       Date:  2008-08-12       Impact factor: 4.304

8.  KSGal6ST is essential for the 6-sulfation of galactose within keratan sulfate in early postnatal brain.

Authors:  Hitomi Hoshino; Tahmina Foyez; Shiori Ohtake-Niimi; Yoshiko Takeda-Uchimura; Makoto Michikawa; Kenji Kadomatsu; Kenji Uchimura
Journal:  J Histochem Cytochem       Date:  2013-10-23       Impact factor: 2.479

9.  Neurocan is dispensable for brain development.

Authors:  X H Zhou; C Brakebusch; H Matthies; T Oohashi; E Hirsch; M Moser; M Krug; C I Seidenbecher; T M Boeckers; U Rauch; R Buettner; E D Gundelfinger; R Fässler
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

10.  Down-regulation of neurocan expression in reactive astrocytes promotes axonal regeneration and facilitates the neurorestorative effects of bone marrow stromal cells in the ischemic rat brain.

Authors:  Li Hong Shen; Yi Li; Qi Gao; Smita Savant-Bhonsale; Michael Chopp
Journal:  Glia       Date:  2008-12       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.